Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study

BACKGROUND: Pegunigalsidase alfa is a novel, PEGylated α-galactosidase-A enzyme-replacement therapy approved in the EU and US to treat patients with Fabry disease (FD). OBJECTIVE/METHODS: BRIDGE is a phase 3 open-label, switch-over study designed to assess safety and efficacy of 12 months of pegunig...

Descripción completa

Detalles Bibliográficos
Autores principales: Linhart, Aleš, Dostálová, Gabriela, Nicholls, Kathy, West, Michael L., Tøndel, Camilla, Jovanovic, Ana, Giraldo, Pilar, Vujkovac, Bojan, Geberhiwot, Tarekegn, Brill-Almon, Einat, Alon, Sari, Chertkoff, Raul, Rocco, Rossana, Hughes, Derralynn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10589982/
https://www.ncbi.nlm.nih.gov/pubmed/37865771
http://dx.doi.org/10.1186/s13023-023-02937-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10589982/
https://www.ncbi.nlm.nih.gov/pubmed/37865771
http://dx.doi.org/10.1186/s13023-023-02937-6

Ejemplares similares